I will now turn the call over to Dean and Brad to provide further details on our second quarter 2012 financial results and our commercial and operations progress worldwide. I will then conclude the highlights of our research and development programs, including anticipated milestones and business priorities for the remainder of the year. Dean.Dean Schorno
Genomic Health's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.